SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

PGDx elio tissue complete CDx

LH·LABCORP HOLDINGS INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA PMA P250036)
Time to market
Already on the market. The test received FDA 510(k) clearance as a tumor profiling test in April 2020, and received FDA PMA approval as a companion diagnostic for BRAF V600E/K in advanced melanoma on August 10, 2026. It is currently commercially available from Labcorp.
Why 3/10
This is an already-approved, commercialized in vitro diagnostic. No pending PDUFA date, pivotal readout, or regulatory decision is scheduled for this product in the next 12 months. For a large-cap company like Labcorp (~$12B+ annual revenue), this single test is a small part of a diversified diagnostics portfolio, so even a meaningful commercial outcome would not be a hard, dated catalyst for the stock.
Actionable Insight NEUTRAL

PGDx elio tissue complete CDx is already FDA-approved and commercialized. No near-term binary catalyst exists for this specific product. For Labcorp investors, the relevant watchpoint is broader adoption trends in precision oncology diagnostics and how Labcorp's kitted solution competes against central-lab models from Foundation Medicine (Roche) and Guardant Health, but this single product is too small to drive LH shares materially. The stock's next scheduled catalyst is ongoing earnings execution across Labcorp's diagnostics and drug-development segments.

Price Chart

Loading chart...

Executive Summary

PGDx elio tissue complete CDx is an FDA-approved companion diagnostic test developed by Labcorp (NYSE: LH) through its 2022 acquisition of Personal Genome Diagnostics. The test uses next-generation sequencing to analyze 505 cancer-related genes from tumor tissue and is specifically approved as a companion diagnostic to identify BRAF V600E/V600K mutations in advanced melanoma, guiding use of BRAF and BRAF/MEK inhibitor therapies. It was originally cleared by the FDA via 510(k) in April 2020 as a tumor profiling test and received PMA approval as a CDx on August 10, 2026. The test is marketed as the first and only FDA-cleared tumor profiling kitted solution, designed for use in hospital and clinical laboratories rather than requiring send-out to central reference labs. For Labcorp, this is a commercial-stage product within a much larger diagnostics and life sciences business, and no upcoming binary regulatory catalyst exists.

How It Works

PGDx elio tissue complete CDx is a laboratory test that uses next-generation DNA sequencing to analyze a tumor tissue sample. It reads the DNA across 505 cancer-related genes to find mutations that can guide treatment decisions. Specifically, the test is FDA-approved as a companion diagnostic to detect BRAF V600E and V600K mutations in advanced melanoma tumors, identifying patients who may respond to BRAF inhibitor or BRAF/MEK inhibitor targeted therapies. It also provides broader tumor genomic profiling information beyond its companion diagnostic claim.

Trial Status

The test achieved FDA PMA approval (P250036) on August 10, 2026, as a companion diagnostic for BRAF V600E/V600K in advanced melanoma. This followed an earlier 510(k) clearance (K192063) in April 2020 for general tumor mutation profiling. The PMA approval was supported by clinical validation demonstrating non-inferiority to existing FDA-approved companion diagnostics.

The Two-Sided Case

▲ Bull Case4
First and only FDA-cleared tumor profiling kitted solution, meaning hospitals and labs can run the test on-site rather than sending samples to central reference labs. This can shorten turnaround time from weeks to days, which the company highlights as a key advantage for advanced melanoma patients.
The FDA PMA approval as a companion diagnostic for BRAF V600E/K provides a regulatory seal that can drive adoption among hospitals seeking to build in-house precision oncology programs. Labcorp claims a clinical success rate above 92%.
The 505-gene panel goes beyond the CDx claim, providing TMB and MSI results plus comprehensive genomic profiling from a single assay, which may support future label expansion for additional CDx indications.
Labcorp acquired PGDx in 2022 for $450M, signaling a strategic commitment to precision oncology. The PMA approval validates this investment and opens a sales channel to hospital laboratories that Labcorp can leverage across its broader oncology portfolio.
▼ Bear Case4
PGDx elio tissue complete CDx is a small incremental product within Labcorp's vast diagnostics portfolio (2022 acquisition of PGDx for $450M was a fraction of Labcorp's ~$12B+ annual revenue); even strong adoption would barely move LH's stock.
The companion diagnostic market is competitive and crowded. FoundationOne CDx (Roche) and Guardant360 CDx (Guardant Health) are entrenched NGS-based competitors with broader FDA-approved CDx claims across multiple therapies and tumor types.
The test's CDx label is limited to BRAF V600E/V600K in melanoma. Broader tumor profiling claims exist under the 510(k) clearance but without companion diagnostic designations for other drugs, limiting the reimbursement and marketing advantage vs competitors.
Medicare reimbursement for the test (PLA code 0250U at approximately $2,950 per test) provides a known revenue floor, but adoption depends on hospital lab budgets and the shift from send-out testing to in-house kitted solutions.

Upcoming Catalysts

  • No near-term binary catalyst for this specific product. Future catalysts could include FDA clearance of additional companion diagnostic claims for other drugs/tumor types using the same test platform, but none are currently announced or scheduled.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

LABCORP HOLDINGS INC. 8-K LH ·Originating report

Sources · 10

Hover a chip for the title
1 ir.labcorp.com2 labcorp.com3 fda.innolitics.com4 cancernetwork.com5 fda.report6 dermatologytimes.com7 nasdaq.com8 ir.labcorp.com9 fda.innolitics.com10 novapharmanews.com